-
1
-
-
84864477617
-
ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
-
McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P,. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14: 803-869.
-
(2012)
Eur J Heart Fail
, vol.14
, pp. 803-869
-
-
McMurray, J.J.1
Adamopoulos, S.2
Anker, S.D.3
Auricchio, A.4
Bohm, M.5
Dickstein, K.6
Falk, V.7
Filippatos, G.8
Fonseca, C.9
Gomez-Sanchez, M.A.10
Jaarsma, T.11
Kober, L.12
Lip, G.Y.13
Maggioni, A.P.14
Parkhomenko, A.15
Pieske, B.M.16
Popescu, B.A.17
Ronnevik, P.K.18
Rutten, F.H.19
Schwitter, J.20
Seferovic, P.21
Stepinska, J.22
Trindade, P.T.23
Voors, A.A.24
Zannad, F.25
Zeiher, A.26
Bax, J.J.27
Baumgartner, H.28
Ceconi, C.29
Dean, V.30
Deaton, C.31
Fagard, R.32
Funck-Brentano, C.33
Hasdai, D.34
Hoes, A.35
Kirchhof, P.36
Knuuti, J.37
Kolh, P.38
McDonagh, T.39
Moulin, C.40
Reiner, Z.41
Sechtem, U.42
Sirnes, P.A.43
Tendera, M.44
Torbicki, A.45
Vahanian, A.46
Windecker, S.47
Bonet, L.A.48
Avraamides, P.49
Ben Lamin, H.A.50
Brignole, M.51
Coca, A.52
Cowburn, P.53
Dargie, H.54
Elliott, P.55
Flachskampf, F.A.56
Guida, G.F.57
Hardman, S.58
Iung, B.59
Merkely, B.60
Mueller, C.61
Nanas, J.N.62
Nielsen, O.W.63
Orn, S.64
Parissis, J.T.65
Ponikowski, P.66
more..
-
2
-
-
84884294190
-
2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
-
American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines
-
Yancy CW, Jessup M, Bozkurt B, Masoudi FA, Butler J, McBride PE, Casey DE Jr, McMurray JJ, Drazner MH, Mitchell JE, Fonarow GC, Peterson PN, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL, American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62: e417-e239.
-
(2013)
J Am Coll Cardiol
, vol.62
, pp. e417-e239
-
-
Yancy, C.W.1
Jessup, M.2
Bozkurt, B.3
Masoudi, F.A.4
Butler, J.5
McBride, P.E.6
Casey, D.E.7
McMurray, J.J.8
Drazner, M.H.9
Mitchell, J.E.10
Fonarow, G.C.11
Peterson, P.N.12
Geraci, S.A.13
Horwich, T.14
Januzzi, J.L.15
Johnson, M.R.16
Kasper, E.K.17
Levy, W.C.18
Riegel, B.19
Sam, F.20
Stevenson, L.W.21
Tang, W.H.22
Tsai, E.J.23
Wilkoff, B.L.24
more..
-
3
-
-
84863614614
-
Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: Prevalence, therapies, and outcomes
-
Steinberg BA, Zhao X, Heidenreich PA, Peterson ED, Bhatt DL, Cannon CP, Hernandez AF, Fonarow GC,. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation 2012; 126: 65-75.
-
(2012)
Circulation
, vol.126
, pp. 65-75
-
-
Steinberg, B.A.1
Zhao, X.2
Heidenreich, P.A.3
Peterson, E.D.4
Bhatt, D.L.5
Cannon, C.P.6
Hernandez, A.F.7
Fonarow, G.C.8
-
4
-
-
84899510381
-
Heart failure with preserved ejection fraction: A clinical dilemma
-
Komajda M, Lam CS,. Heart failure with preserved ejection fraction: a clinical dilemma. Eur Heart J. 2014; 35: 1022-1032.
-
(2014)
Eur Heart J.
, vol.35
, pp. 1022-1032
-
-
Komajda, M.1
Lam, C.S.2
-
5
-
-
84892991005
-
HFNEF, HFPEF, HF-PEF, or DHF: What is in an acronym?
-
Sanderson JE,. HFNEF, HFPEF, HF-PEF, or DHF: what is in an acronym? JACC Heart Fail 2014; 2: 93-94.
-
(2014)
JACC Heart Fail
, vol.2
, pp. 93-94
-
-
Sanderson, J.E.1
-
6
-
-
84893321088
-
Impaired systolic function by strain imaging in heart failure with preserved ejection fraction
-
Kraigher-Krainer E, Shah AM, Gupta DK, Santos A, Claggett B, Pieske B, Zile MR, Voors AA, Lefkowitz MP, Packer M, McMurray JJ, Solomon SD,. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. J Am Coll Cardiol 2014; 63: 447-456.
-
(2014)
J Am Coll Cardiol
, vol.63
, pp. 447-456
-
-
Kraigher-Krainer, E.1
Shah, A.M.2
Gupta, D.K.3
Santos, A.4
Claggett, B.5
Pieske, B.6
Zile, M.R.7
Voors, A.A.8
Lefkowitz, M.P.9
Packer, M.10
McMurray, J.J.11
Solomon, S.D.12
-
7
-
-
84874367056
-
Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: The ALDO-DHF randomized controlled trial
-
Aldo-DHF Investigators
-
Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W, Duvinage A, Stahrenberg R, Durstewitz K, Loffler M, Dungen HD, Tschope C, Herrmann-Lingen C, Halle M, Hasenfuss G, Gelbrich G, Pieske B, Aldo-DHF Investigators. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the ALDO-DHF randomized controlled trial. JAMA 2013; 309: 781-791.
-
(2013)
JAMA
, vol.309
, pp. 781-791
-
-
Edelmann, F.1
Wachter, R.2
Schmidt, A.G.3
Kraigher-Krainer, E.4
Colantonio, C.5
Kamke, W.6
Duvinage, A.7
Stahrenberg, R.8
Durstewitz, K.9
Loffler, M.10
Dungen, H.D.11
Tschope, C.12
Herrmann-Lingen, C.13
Halle, M.14
Hasenfuss, G.15
Gelbrich, G.16
Pieske, B.17
-
8
-
-
84875531214
-
Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: A randomized clinical trial
-
RELAX trial
-
Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO, O'Connor CM, Felker GM, Goldsmith SR, Bart BA, McNulty SE, Ibarra JC, Lin G, Oh JK, Patel MR, Kim RJ, Tracy RP, Velazquez EJ, Anstrom KJ, Hernandez AF, Mascette AM, Braunwald E, RELAX trial. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2013; 309: 1268-1277.
-
(2013)
JAMA
, vol.309
, pp. 1268-1277
-
-
Redfield, M.M.1
Chen, H.H.2
Borlaug, B.A.3
Semigran, M.J.4
Lee, K.L.5
Lewis, G.6
Lewinter, M.M.7
Rouleau, J.L.8
Bull, D.A.9
Mann, D.L.10
Deswal, A.11
Stevenson, L.W.12
Givertz, M.M.13
Ofili, E.O.14
O'Connor, C.M.15
Felker, G.M.16
Goldsmith, S.R.17
Bart, B.A.18
McNulty, S.E.19
Ibarra, J.C.20
Lin, G.21
Oh, J.K.22
Patel, M.R.23
Kim, R.J.24
Tracy, R.P.25
Velazquez, E.J.26
Anstrom, K.J.27
Hernandez, A.F.28
Mascette, A.M.29
Braunwald, E.30
more..
-
9
-
-
84898713808
-
Spironolactone for heart failure with preserved ejection fraction
-
TOPCAT Investigators
-
Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O'Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM, TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 370: 1383-1392.
-
(2014)
N Engl J Med
, vol.370
, pp. 1383-1392
-
-
Pitt, B.1
Pfeffer, M.A.2
Assmann, S.F.3
Boineau, R.4
Anand, I.S.5
Claggett, B.6
Clausell, N.7
Desai, A.S.8
Diaz, R.9
Fleg, J.L.10
Gordeev, I.11
Harty, B.12
Heitner, J.F.13
Kenwood, C.T.14
Lewis, E.F.15
O'Meara, E.16
Probstfield, J.L.17
Shaburishvili, T.18
Shah, S.J.19
Solomon, S.D.20
Sweitzer, N.K.21
Yang, S.22
McKinlay, S.M.23
more..
-
10
-
-
84867745957
-
Prospective comparison of ARNI with ARB on Management of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: A phase 2 double-blind randomised controlled trial
-
Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJ,. Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012; 380: 1387-1395.
-
(2012)
Lancet
, vol.380
, pp. 1387-1395
-
-
Solomon, S.D.1
Zile, M.2
Pieske, B.3
Voors, A.4
Shah, A.5
Kraigher-Krainer, E.6
Shi, V.7
Bransford, T.8
Takeuchi, M.9
Gong, J.10
Lefkowitz, M.11
Packer, M.12
McMurray, J.J.13
-
11
-
-
57349142933
-
Irbesartan in patients with heart failure and preserved ejection fraction
-
I-PRESERVE Investigators
-
Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A, I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359: 2456-2467.
-
(2008)
N Engl J Med
, vol.359
, pp. 2456-2467
-
-
Massie, B.M.1
Carson, P.E.2
McMurray, J.J.3
Komajda, M.4
McKelvie, R.5
Zile, M.R.6
Anderson, S.7
Donovan, M.8
Iverson, E.9
Staiger, C.10
Ptaszynska, A.11
-
12
-
-
33644878739
-
Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients
-
Solomon SD, Anavekar N, Skali H, McMurray JJ, Swedberg K, Yusuf S, Granger CB, Michelson EL, Wang D, Pocock S, Pfeffer MA,. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 2005; 112: 3738-3744.
-
(2005)
Circulation
, vol.112
, pp. 3738-3744
-
-
Solomon, S.D.1
Anavekar, N.2
Skali, H.3
McMurray, J.J.4
Swedberg, K.5
Yusuf, S.6
Granger, C.B.7
Michelson, E.L.8
Wang, D.9
Pocock, S.10
Pfeffer, M.A.11
-
13
-
-
34547837711
-
Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: A report from the OPTIMIZE-HF registry
-
OPTIMIZE-HF Investigators and Hospitals
-
Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, O'Connor CM, Sun JL, Yancy CW, Young JB, OPTIMIZE-HF Investigators and Hospitals. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF registry. J Am Coll Cardiol 2007; 50: 768-777.
-
(2007)
J Am Coll Cardiol
, vol.50
, pp. 768-777
-
-
Fonarow, G.C.1
Stough, W.G.2
Abraham, W.T.3
Albert, N.M.4
Gheorghiade, M.5
Greenberg, B.H.6
O'Connor, C.M.7
Sun, J.L.8
Yancy, C.W.9
Young, J.B.10
-
14
-
-
79955759374
-
Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum
-
discussion 2014
-
Borlaug BA, Redfield MM,. Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation 2011; 123: 2006-2013; discussion 2014.
-
(2011)
Circulation
, vol.123
, pp. 2006-2013
-
-
Borlaug, B.A.1
Redfield, M.M.2
-
15
-
-
84903154515
-
Implications of coronary artery disease in heart failure with preserved ejection fraction
-
Hwang SJ, Melenovsky V, Borlaug BA,. Implications of coronary artery disease in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2014; 63: 2817-2827.
-
(2014)
J Am Coll Cardiol.
, vol.63
, pp. 2817-2827
-
-
Hwang, S.J.1
Melenovsky, V.2
Borlaug, B.A.3
-
16
-
-
61349151722
-
Comparison of ventricular structure and function in Chinese patients with heart failure and ejection fractions >55% versus 40% to 55% versus <40%
-
He KL, Burkhoff D, Leng WX, Liang ZR, Fan L, Wang J, Maurer MS,. Comparison of ventricular structure and function in Chinese patients with heart failure and ejection fractions >55% versus 40% to 55% versus <40%. Am J Cardiol 2009; 103: 845-851.
-
(2009)
Am J Cardiol
, vol.103
, pp. 845-851
-
-
He, K.L.1
Burkhoff, D.2
Leng, W.X.3
Liang, Z.R.4
Fan, L.5
Wang, J.6
Maurer, M.S.7
-
17
-
-
0037108639
-
Outcome of congestive heart failure in elderly persons: Influence of left ventricular systolic function. The Cardiovascular Health Study
-
Gottdiener JS, McClelland RL, Marshall R, Shemanski L, Furberg CD, Kitzman DW, Cushman M, Polak J, Gardin JM, Gersh BJ, Aurigemma GP, Manolio TA,. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med 2002; 137: 631-639.
-
(2002)
Ann Intern Med
, vol.137
, pp. 631-639
-
-
Gottdiener, J.S.1
McClelland, R.L.2
Marshall, R.3
Shemanski, L.4
Furberg, C.D.5
Kitzman, D.W.6
Cushman, M.7
Polak, J.8
Gardin, J.M.9
Gersh, B.J.10
Aurigemma, G.P.11
Manolio, T.A.12
-
18
-
-
0041356972
-
Natural history of asymptomatic left ventricular systolic dysfunction in the community
-
Wang TJ, Evans JC, Benjamin EJ, Levy D, LeRoy EC, Vasan RS,. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation 2003; 108: 977-982.
-
(2003)
Circulation
, vol.108
, pp. 977-982
-
-
Wang, T.J.1
Evans, J.C.2
Benjamin, E.J.3
Levy, D.4
Leroy, E.C.5
Vasan, R.S.6
-
19
-
-
0042332267
-
Prognostic implications of ejection fraction from linear echocardiographic dimensions: The Strong Heart Study
-
Devereux RB, Roman MJ, Palmieri V, Liu JE, Lee ET, Best LG, Fabsitz RR, Rodeheffer RJ, Howard BV,. Prognostic implications of ejection fraction from linear echocardiographic dimensions: the Strong Heart Study. Am Heart J. 2003; 146: 527-534.
-
(2003)
Am Heart J.
, vol.146
, pp. 527-534
-
-
Devereux, R.B.1
Roman, M.J.2
Palmieri, V.3
Liu, J.E.4
Lee, E.T.5
Best, L.G.6
Fabsitz, R.R.7
Rodeheffer, R.J.8
Howard, B.V.9
-
20
-
-
34548154261
-
Prognosis of all-cause heart failure and borderline left ventricular systolic dysfunction: 5 year mortality follow-up of the Echocardiographic Heart of England Screening Study (ECHOES)
-
Midlands Research Practices Consortium (MidReC)
-
Hobbs FD, Roalfe AK, Davis RC, Davies MK, Hare R, Midlands Research Practices Consortium (MidReC). Prognosis of all-cause heart failure and borderline left ventricular systolic dysfunction: 5 year mortality follow-up of the Echocardiographic Heart of England Screening Study (ECHOES). Eur Heart J 2007; 28: 1128-1134.
-
(2007)
Eur Heart J
, vol.28
, pp. 1128-1134
-
-
Hobbs, F.D.1
Roalfe, A.K.2
Davis, R.C.3
Davies, M.K.4
Hare, R.5
-
21
-
-
84880118241
-
The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: An individual patient data meta-analysis
-
Meta-analysis Global Group in Chronic Heart Failure (MAGGIC)
-
Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J 2012; 33: 1750-1757.
-
(2012)
Eur Heart J
, vol.33
, pp. 1750-1757
-
-
-
22
-
-
0041408234
-
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial
-
CHARM Investigators and Committees
-
Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777-781.
-
(2003)
Lancet
, vol.362
, pp. 777-781
-
-
Yusuf, S.1
Pfeffer, M.A.2
Swedberg, K.3
Granger, C.B.4
Held, P.5
McMurray, J.J.6
Michelson, E.L.7
Olofsson, B.8
Ostergren, J.9
-
23
-
-
84875442830
-
The influence of left ventricular ejection fraction on the effectiveness of cardiac resynchronization therapy: MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy)
-
Kutyifa V, Kloppe A, Zareba W, Solomon SD, McNitt S, Polonsky S, Barsheshet A, Merkely B, Lemke B, Nagy VK, Moss AJ, Goldenberg I,. The influence of left ventricular ejection fraction on the effectiveness of cardiac resynchronization therapy: MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy). J Am Coll Cardiol 2013; 61: 936-944.
-
(2013)
J Am Coll Cardiol
, vol.61
, pp. 936-944
-
-
Kutyifa, V.1
Kloppe, A.2
Zareba, W.3
Solomon, S.D.4
McNitt, S.5
Polonsky, S.6
Barsheshet, A.7
Merkely, B.8
Lemke, B.9
Nagy, V.K.10
Moss, A.J.11
Goldenberg, I.12
|